{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"121.65","value":"65.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.3 mg per m\\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.","id":"OG000","title":"Bortezomib"}],"paramType":"MEAN","populationDescription":"The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.","reportingStatus":"POSTED","timeFrame":"0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1","title":"Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1","type":"PRIMARY","unitOfMeasure":"Hour"}